Clinical Trial

TAC-STIM™ Non-Invasive Vagal Nerve Stimulation Selected for Inclusion in the Air Force Research Laboratories Real-Time Assessing and Augmenting Cognitive Performance in Extreme Environments Project

ROCKAWAY, N.J., June 27, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced…

1 year ago

Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association’s Annual Conference

FARMINGTON HILLS, Mich., June 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused…

1 year ago

Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors

WARRINGTON, Pa., June 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company…

1 year ago

ORYZON Announces Voting Results from its 2023 Annual General Meeting of Shareholders

All resolutions were approved.35% of the issued shares represented.MADRID, Spain and BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics,…

1 year ago

Assure Holdings Expands Service Offerings to Address the High Growth EEG Services Market

Signs Diagnostics Services Agreement with Neurovative DiagnosticsDENVER, June 27, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”)…

1 year ago

Microbot Medical Announces $2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

HINGHAM, Mass., June 27, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into…

1 year ago

Journal of Clinical Oncology Publishes Results of Corcept’s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer

Relacorilant plus nab-paclitaxel improved progression-free survival (PFS), duration of response (DoR) and overall survival (OS), without increasing side effects, compared…

1 year ago

Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma

SOUTH SAN FRANCISCO, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing…

1 year ago

Anavex Life Sciences and Partex Group Announce Strategic Partnership to Leverage AI for Drug Development and Healthcare Sales Marketing Building a Patient-Centric Digital Ecosystem

Anavex and Partex agreed to enter into a strategic partnership to leverage Partex’s proprietary AI (Artificial Intelligence) technology for Anavex’s…

1 year ago

Arch Biopartners Receives Permission From U.S. FDA to Proceed With Phase II Acute Kidney Injury Trial

Approval from FDA to initiate Phase II trial with LSALT peptide to target cardiac surgery-associated acute kidney injury (CS-AKI)LSALT peptide…

1 year ago